Finasteride carries several serious side effects that go beyond what many people expect from a common hair loss or prostate medication. The most significant risks involve persistent sexual dysfunction, mood changes including suicidal thoughts, breast tissue changes, and potential effects on fertility and cognition. In clinical studies, up to 15% of men experienced some form of sexual side effect within the first year of treatment, and regulatory agencies in the U.S. and Europe have updated their warnings multiple times as new evidence has emerged.
Sexual Dysfunction
Sexual side effects are the most frequently reported serious problem with finasteride. In clinical data, erectile dysfunction affected roughly 9.6% of men, decreased libido hit about 7.7%, and ejaculation problems occurred in around 5.7%. Those numbers come from men who weren’t told in advance what side effects to expect. When men were informed beforehand, the rates jumped considerably, to 30.9% for erectile dysfunction and 23.6% for decreased libido, suggesting that awareness and anxiety amplify the experience. Regardless of the role psychology plays, the physical effects are real for many users.
What makes these side effects particularly concerning is that they don’t always go away after stopping the drug. The FDA’s current Propecia label specifically lists “sexual dysfunction that continued after discontinuation of treatment,” covering erectile dysfunction, libido disorders, ejaculation disorders, and orgasm disorders. The UK’s medicines regulator has received 426 reports of finasteride-related sexual dysfunction, and in almost half of those cases, the outcome was recorded as “not recovered” or “not resolved.” That persistence is what separates finasteride’s sexual side effects from those of many other medications.
Depression and Suicidal Thoughts
The European Medicines Agency confirmed suicidal ideation as a recognized side effect of finasteride at both the 1 mg and 5 mg doses. Their review identified 325 relevant cases of suicidal thoughts reported through their safety monitoring system, with 313 linked to finasteride specifically. Most of these cases involved men taking the drug for hair loss rather than prostate enlargement. The exact frequency is classified as “unknown” because the data doesn’t allow a reliable estimate, but the signal was strong enough for regulators to act.
Product labels in both Europe and the U.S. now warn about depression, depressed mood, and suicidal ideation and behavior. In the EU, finasteride 1 mg packages now include a patient card reminding users of these risks. The guidance is straightforward: anyone experiencing mood changes while taking finasteride should stop the 1 mg dose and seek medical advice. This is especially relevant because sexual side effects themselves can contribute to mood changes, creating a compounding effect that isn’t always easy to untangle.
Breast Changes and Cancer Risk
Finasteride can cause breast tissue growth in men, a condition called gynecomastia. This affected about 0.4% of users in monitoring studies, making it uncommon but not rare. Symptoms include breast enlargement, tenderness, pain, and occasionally nipple discharge. The FDA label advises reporting any breast lumps, pain, or discharge promptly.
More concerning is a possible link to male breast cancer. In clinical trials, men who took finasteride 5 mg developed breast cancer at a rate of 7.8 per 100,000 patient-years, compared to 3.8 per 100,000 in men who didn’t take the drug. That difference didn’t reach statistical significance, but it was enough for the UK’s medicines regulator to conclude that “an increased risk of male breast cancer associated with finasteride use cannot be excluded.” Male breast cancer is listed on the FDA’s postmarketing label for Propecia.
Effects on the Brain and Memory
Finasteride doesn’t just block the conversion of testosterone to its more potent form. It also disrupts the production of certain brain-active hormones called neurosteroids, which play roles in mood regulation, memory formation, and cognitive function. These neurosteroids help maintain the brain’s ability to form new connections and support learning processes, particularly in the hippocampus, a region central to memory.
Animal studies have demonstrated measurable cognitive effects. Rats given finasteride showed significant spatial memory deficits and reduced enzyme activity in brain regions tied to memory. Mouse studies found that finasteride reduced the creation of new brain cells and immature neurons in the hippocampus, though this effect appeared to be reversible once the drug was stopped. In humans, reports of “brain fog,” memory difficulties, and cognitive changes have been consistent enough to warrant ongoing investigation, though large-scale clinical data on cognitive effects is still limited.
Fertility and Sperm Quality
Some men taking finasteride have experienced poor sperm quality or infertility. The FDA label lists “male infertility and/or poor seminal quality” as a postmarketing adverse reaction, alongside decreased ejaculate volume. The NHS notes this is not a common side effect and that sperm quality typically returns to normal after stopping finasteride. Still, for men actively trying to conceive, this is a practical risk worth knowing about before starting treatment.
Post-Finasteride Syndrome
Post-finasteride syndrome, or PFS, refers to a cluster of symptoms that persist for months or years after stopping the drug. It’s considered rare but serious, and it primarily affects younger men. The reported symptoms span three categories. Sexual symptoms include erectile dysfunction, low libido, genital numbness, orgasm disorders, and genital shrinkage. Psychiatric symptoms include anxiety, depression, insomnia, brain fog, memory loss, panic attacks, and suicidal ideation. Physical symptoms include fatigue, dizziness, muscle tremors, and breast changes.
In reported PFS cases, patients consistently describe erectile dysfunction, anxiety, depression, feelings of isolation, and insomnia as their most debilitating symptoms. The underlying mechanism isn’t well understood, but the prevailing theory centers on lasting disruption to neurosteroid production and hormonal signaling. Health authorities in multiple countries have acknowledged PFS as a potential consequence of finasteride use, though it remains a condition without established diagnostic criteria or proven treatment. The UK regulator’s finding that nearly half of sexual dysfunction reports were marked “not recovered” gives some indication of how persistent these effects can be for the subset of men who develop them.
What the Labels Now Say
The FDA updated the Propecia label in July 2022 to include postmarketing reports of persistent sexual dysfunction, male breast cancer, depression, and suicidal ideation and behavior. Testicular pain and blood in semen are also listed. The European Medicines Agency took the additional step of requiring patient cards in 1 mg finasteride packaging across Europe, specifically to alert users about mood-related and sexual risks.
These label changes reflect a pattern: finasteride’s risk profile has been revised repeatedly as real-world data accumulated beyond what clinical trials initially captured. The original trials showed relatively modest rates of sexual side effects that typically resolved. Postmarketing surveillance told a more complex story, one where some men experienced effects that didn’t resolve and where psychiatric risks became increasingly difficult to dismiss.